

Embargoed: 0700hrs, 11 May 2006

AKERS BIOSCIENCES, INC.
(“Akers” or the “Company”)
Appointment of a Director

Akers Biosciences, Inc., the United States based developer, manufacturer, and supplier of rapid, point of care screening and testing products, is pleased to announce the appointment of Thomas A. Nicolette as Non-Executive Director, effective immediately. Akers believes that Mr. Nicolette's background in sales, manufacturing and experience as Chief Executive Officer of several companies publicly listed in the U.S. will be of great benefit to the Company.

Mr. Nicolette replaces Geoffrey Vero on the Company's Board of Directors, whose term as Non-Executive Director expires in 90 days, ensuring an orderly transition. The Company wishes to thank Mr. Vero for his service to the Board, and his capable leadership of the Audit Committee.

The directorships held by Mr. Nicolette, aged 55, over the five years preceding the date of appointment are as follows:

Current directorships

SenTech EAS Corporation

Director – Corporate Secretary and Treasurer

Designs, manufacturers, installs and services Electronic Security Systems for retail, commercial and industrial firms. Based in Pompano Beach, Florida

IDENTIF GmbH Director – International Business Development

Has developed patented new methods of authentication based on molecular and optical markings used for anti-counterfeiting. Based in Erlangen, Germany.

Global Securities Technologies, Inc. Chairman of the Board

Based in San Juan, Puerto Rico.

Former directorships held during last five years

EXAQT SA DE CV

Chairman of the Board

Designs, manufacturers, installs and services Electronic Security Systems for retail, commercial and industrial firms. Based in Mexico City, Mexico.

TRI-MEX Group Limited
Executive Director

Has developed monitoring and response solutions to protect high value and/or hazardous cargo in transit on land and sea. Based in London with operations in Oslo, Norway.

CROSSOFF, Inc.
Director

Served as president of DNAT and a Director of CrossOff, Inc. (TSE:OFF) based in Los Angeles, California.

DNA TECHNOLOGIES, INC.
Chairman and President
Chief Executive Officer, Director

Owns patented technology which has harnessed the power of genetic code, providing a solution to the problems of counterfeiting, forgery and product diversion. Sold to CrossOff, Inc. in October 2001. Based in Halifax, Nova Scotia, Canada.

The Company has granted Mr. Nicolette an option to subscribe for 110,000 Common Shares. The exercise price of such options will be \$1.32 per Common Share. The options shall vest as follows: 47,000 options will vest six months after the date of appointment and the balance of options will vest in 18 equal monthly installments of 3,500 options per completed month of service as a Non-Executive Director commencing six months after the date of appointment.

There is no further information required to be disclosed pursuant to the AIM Rules.

For further information please contact:

Dr. Ray Akers	Chief Executive Officer, Akers Biosciences, Inc.	020 7917 9476
Paul Freedman	Chief Financial Officer, Akers Biosciences, Inc.	001 856 848 8698
Bill Roberts	CTC, Inc.	001 937 434 2700
Ben Simons	Hansard Communications	020 7245 1100